Clinical Trials Logo

Filter by:
NCT ID: NCT05076682 Recruiting - Clinical trials for Triple-negative Breast Cancer

Reverse Triple Negative Immune Resistant Breast Cancer

Renaissance
Start date: June 30, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label, three-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, or efavirenz) with immune checkpoint inhibitor in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

NCT ID: NCT05076097 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.

NCT ID: NCT05076071 Recruiting - Clinical trials for Pediatric, Solid Tumors, NGS

Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors

Start date: August 6, 2021
Phase:
Study type: Observational

Samples of 200 patients with pediatric malignant solid tumors will prospectively be collected. Selected samples are sufficient for next generation sequencing(NGS) and available for follow-up information. Multi-omics techniques such as DNA and RNA panel will be used to study driver genes for the development of malignant solid tumors in children, and to explore the pathogenic mechanism. The aim of this study is to explore new biomarkers for the diagnosis and treatment for childhood malignant solid tumors.

NCT ID: NCT05075681 Recruiting - Clinical trials for Peripheral Blood Stem Cell Transplantation

Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

NCT ID: NCT05075512 Recruiting - Clinical trials for Breast Neoplasm Female

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine monotherapy or combination regimens, both with benefit diminishing as resistance develops. Nowadays, various studies have demonstrated that estrogen interacts with many angiogenic pathways and is an important mechanism for resistance leading to the question of whether combination with antiangiogenesis and antiestrogen therapies could be an appropriate therapeutic modality. Anlotinib is a novel multi-target tyrosine kinase inhibitor that effectively inhibit VEGFR, FGFR, PDGFR, c-KIT, c-MET and RET. Previous studies have proven the efficacy of both anlotinib monotherapy and combination regimens in advanced breast cancer. This phase II study aims to preliminarily evaluate the efficacy and safety of anlotinib combined with endocrine therapy.

NCT ID: NCT05075460 Recruiting - T-cell Lymphoma Clinical Trials

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Start date: October 1, 2021
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

NCT ID: NCT05075447 Recruiting - Clinical trials for Lack of; Attention, With Hyperactivity (ADHD)

Treatment Plan for ADHD With Indifferent Traits

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

For children with ADHD aged 4-10 at the time of enrollment, starting from preschool, focusing on apathy and emotional control, using psycho-behavioral measurements, EEG experiments, and eye tracking technology to evaluate and implement targeted Sexual intervention and six-month follow-up. Establish a diagnosis and treatment decision analysis model and psychological treatment plan for ODD/CD.

NCT ID: NCT05075083 Recruiting - COVID-19 Clinical Trials

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD

Start date: October 8, 2021
Phase: Phase 4
Study type: Interventional

Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .

NCT ID: NCT05075070 Recruiting - HIV Infections Clinical Trials

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected

Start date: October 8, 2021
Phase: Phase 4
Study type: Interventional

Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .

NCT ID: NCT05075057 Recruiting - COVID-19 Clinical Trials

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD

Start date: October 8, 2021
Phase: Phase 4
Study type: Interventional

Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .